Immorta Bio's AI-designed 9-amino-acid peptide SenoMune-0257 targets senescent cells
DavidmComfort · x · 2026-10-24
Miami-based Immorta Bio says it has completed preclinical studies for SenoMune-0257, an AI-designed nine-amino-acid synthetic peptide that prompts T cells to clear senescent "zombie cells," with first human evaluation planned before year-end.
Key points:
- The molecule is tiny by drug standards (9 amino acids); AI helped identify it
- Senescent cells stop dividing but linger, contributing to chronic inflammation, tissue deterioration and disease progression
- The company argues its immunotherapy approach avoids the off-target toxicity of direct senolytics and generates durable immunological memory
- Clearing senescent cells has shown benefits in models of cardiovascular, liver/kidney, pulmonary, fibrosis, neurodegeneration and cancer, plus extended lifespan in mice
More from Research
- How visual evidence gets encoded: different priors interpolate into different hallucinations — debreuil · 2026-10-24
- MIT Team: Only 2 of 286 TB Antigen Candidates Detected on MHC-I — BrianHie · 2026-10-24
- NYU Biology opens tenure-track search for AI-enabled biology professor — lucapinello · 2026-10-24
- Cancer center's $300-400K GPU dilemma: RTX Pro 5000 pairs vs one 8-GPU box for AlphaFold — starkruzr · 2026-10-24
- Kijito builds a 'prosthetic hippocampus' for LLMs, cutting memory tokens ~20x — jasonridesabike · 2026-10-24
- Steve Byrnes' Brain-Like-AGI Safety Series: 15 Posts From Neuroscience to Alignment — fleetwood___ · 2026-10-24